Vinblastine, Bleomycin, and Methotrexate Chemotherapy Plus Extended-Field Radiotherapy in Early, Favorably Presenting, Clinically Staged Hodgkin's Patients: The Gruppo Italiano per lo Studio dei Linfomi Experience

Paolo G. Gobbi, Carlo Pieresca, Antonio Frassoldati, Mario Carotenuto, Nicola Di Renzo, Antonio La Sala, Raffaella Bertè, Paolo Avanzini, Massimo Federico, Vittorio Silingardi, Edoardo Ascari

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To ascertain whether vinblastine, bleomycin, and methotrexate (VBM) (CT) combined with extended-field radiotherapy (EF RT) is effective enough to spare laparotomy in early, favorably presenting Hodgkin's disease (HD) patients. Patients and Methods: Fifty patients with clinical stage IA or IIA HD with favorable histology and no bulky masses entered a prospective multicenter study started in January 1988. The median follow-up time was 38 months. Results: All patients achieved a complete remission (CR). Five relapsed after 3 to 40 months and underwent successful salvage therapy. The actuarial remission rate was 0.89% at 3 years and 0.82% at 5 years. Two patients died in CR: one of severe pulmonary toxicity, the other of a second neoplasia (adenocarcinoma of the lung), 2 and 43 months after the end of therapy, respectively. The hematologic toxicity recorded during VBM CT was mild on the whole. Major toxicity was represented by pulmonary side effects and neurologic symptoms. Multiple regression analysis demonstrated that pulmonary toxicity was significantly related only to the amount of RT delivered to the mediastinum and not to the relative dose of bleomycin, to the dose-intensities of the three drugs in the regimen, or to patient age or sex. The same statistical technique showed that the only clinical factor related to grade of neurotoxicity was vinblastine dosage. Conclusion: VBM CT combined with EF RT is an effective treatment for early, clinically staged, favorable HD patients. However, the toxicity of this combination suggests that certain modifications should be evaluated.

Original languageEnglish
Pages (from-to)527-533
Number of pages7
JournalJournal of Clinical Oncology
Volume14
Issue number2
Publication statusPublished - Feb 1996

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Vinblastine, Bleomycin, and Methotrexate Chemotherapy Plus Extended-Field Radiotherapy in Early, Favorably Presenting, Clinically Staged Hodgkin's Patients: The Gruppo Italiano per lo Studio dei Linfomi Experience'. Together they form a unique fingerprint.

Cite this